Bosse T - Search Results

1

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.

Horeweg N, Nout RA, Jürgenliemk-Schulz IM, Lutgens LCHW, Jobsen JJ, Haverkort MAD, Mens JWM, Slot A, Wortman BG, de Boer SM, Stelloo E, Verhoeven-Adema KW, Putter H, Smit VTHBM, Bosse T, Creutzberg CL; PORTEC Study Group. Horeweg N, et al. Among authors: bosse t. J Clin Oncol. 2023 Sep 20;41(27):4369-4380. doi: 10.1200/JCO.23.00062. Epub 2023 Jul 24. J Clin Oncol. 2023. PMID: 37487144 Free PMC article.

2

Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.

Nout RA, Bosse T, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, van Eijk R, Ter Haar NT, Smit VT. Nout RA, et al. Among authors: bosse t. Gynecol Oncol. 2012 Sep;126(3):466-73. doi: 10.1016/j.ygyno.2012.05.012. Epub 2012 May 15. Gynecol Oncol. 2012. PMID: 22609107

3

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.

Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT. Bosse T, et al. Mod Pathol. 2013 Nov;26(11):1525-35. doi: 10.1038/modpathol.2013.96. Epub 2013 May 24. Mod Pathol. 2013. PMID: 23702729 Free article.

4

High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.

Stelloo E, Nout RA, Naves LC, Ter Haar NT, Creutzberg CL, Smit VT, Bosse T. Stelloo E, et al. Among authors: bosse t. Gynecol Oncol. 2014 May;133(2):197-204. doi: 10.1016/j.ygyno.2014.02.012. Epub 2014 Feb 18. Gynecol Oncol. 2014. PMID: 24556061

5

Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.

Spaans VM, Trietsch MD, Crobach S, Stelloo E, Kremer D, Osse EM, Haar NT, van Eijk R, Muller S, van Wezel T, Trimbos JB, Bosse T, Smit VT, Fleuren GJ. Spaans VM, et al. Among authors: bosse t. PLoS One. 2014 Mar 26;9(3):e93451. doi: 10.1371/journal.pone.0093451. eCollection 2014. PLoS One. 2014. PMID: 24671188 Free PMC article.

6

L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.

Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk-Schulz IM, Jobsen JJ, Creutzberg CL, Smit VT. Bosse T, et al. Eur J Cancer. 2014 Oct;50(15):2602-10. doi: 10.1016/j.ejca.2014.07.014. Epub 2014 Aug 7. Eur J Cancer. 2014. PMID: 25126672

7

Prognostic significance of POLE proofreading mutations in endometrial cancer.

Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL, Bosse T. Church DN, et al. Among authors: bosse t. J Natl Cancer Inst. 2014 Dec 12;107(1):402. doi: 10.1093/jnci/dju402. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25505230 Free PMC article.

8

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL. Stelloo E, et al. Among authors: bosse t. Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27. Mod Pathol. 2015. PMID: 25720322 Free article.

9

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.

van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, Smit VT, Nijman HW, Bosse T, Church DN. van Gool IC, et al. Among authors: bosse t. Clin Cancer Res. 2015 Jul 15;21(14):3347-3355. doi: 10.1158/1078-0432.CCR-15-0057. Epub 2015 Apr 15. Clin Cancer Res. 2015. PMID: 25878334 Free PMC article.

10

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.

Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA. Bosse T, et al. Eur J Cancer. 2015 Sep;51(13):1742-50. doi: 10.1016/j.ejca.2015.05.015. Epub 2015 Jun 3. Eur J Cancer. 2015. PMID: 26049688 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

187 results

Search Page